Novo Nordisk (NVO) and Viatris (VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

Novo Nordisk plans to invest approximately $158 million into revamping its Montes Claros manufacturing facility in Minas Gerais, Brazil, Bloomberg reported Oct. 5.

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Sensex, Nifty updates on 7 October 2024 - Equity benchmark indices, Sensex and Nifty, extended their losing streak to a sixth ...

Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.

Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic ...